Table 3.
Intra-group analysis in GlyAc group at the three time points. Characteristic: variable taken into account;
p-value: test p-value (see the text for abbreviations and further details)
| Characteristic | Time T0 | Time T1 | Time T2 | p-value | Post-hoc analysis | ||
| T0 vs T1 | T1 vs T2 | T0 vs T2 | |||||
| Compliance | 0.9999 | ||||||
| good | 26 (100%) | 26 (100%) | |||||
| Tolerability | 0.9999 | ||||||
| good | 24 (92.31%) | 24 (92.31%) | |||||
| fairly good | 2 (7.69%) | 2 (7.69%) | |||||
| Decongestants use | 8 (30.77%) | 4 (15.38%) | 3 (11.54%) | 0.1482 | |||
| Systemic antihistamines use | 7 (26.92%) | 3 (11.54%) | 2 (7.69%) | 0.0150 | 0.1365 | 0.9519 | 0.0760 |
| SIGNS | |||||||
| Turbinate Hypertrophy | 26 (100%) | 26 (100%) | 14 (53.85%) | <0.0001 | 0.9999 | 0.0016 | 0.0016 |
| Watery Rhinorrhea | 21 (80.77%) | 21 (80.77%) | 10 (38.46%) | <0.0001 | 0.9999 | 0.0029 | 0.0029 |
| Post-Nasal Drip | 21 (80.77%) | 20 (76.92%) | 9 (34.62%) | <0.0001 | 0.9999 | 0.0029 | 0.0015 |
| Pale Mucosa | 25 (96.15%) | 21 (80.77%) | 8 (30.77%) | <0.0001 | 0.3750 | 0.0029 | <0.0001 |
| NASAL AIRFLOW | |||||||
| Inspiratory Resistance | 1.3 (0.25) | 1.04 (0.18) | 0.64 (0.18) | <0.0001 | 0.0025 | <0.0001 | 0.0025 |
| Expiratory Resistance | 1.49 (0.16) | 1.14 (0.21) | 0.65 (0.21) | <0.0001 | 0.0162 | <0.0001 | 0.0061 |
| Nasal Decongestant Test Insp. | 0.95 (0.1) | 0.74 (0.16) | 0.42 (0.17) | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| Nasal Decongestant Test Exp. | 1.03 (0.1) | 0.79 (0.15) | 0.46 (0.2) | <0.0001 | 0.0001 | <0.0001 | 0.0001 |
| SYMPTOMS | |||||||
| VAS Nasal Discomfort | 6.34 (2.74) | 3.82 (2.02) | 1.67 (2.3) | <0.0001 | 0.9999 | 0.0055 | <0.0001 |
| VAS Nasal Obstruction | 7.36 (1.57) | 3.85 (1.51) | 1.54 (1.99) | <0.0001 | 0.9999 | 0.0055 | <0.0001 |
| VAS Rhinorrhea | 6.88 (1.98) | 3.54 (1.57) | 1.77 (1.96) | <0.0001 | 0.9999 | 0.0015 | <0.0001 |
| VAS Itching | 4.71 (3.36) | 2 (1.82) | 0.88 (1.17) | <0.0001 | 0.9737 | 0.0052 | 0.0006 |
| VAS Sneezing | 5.7 (2.86) | 2.72 (2.11) | 1.36 (1.67) | <0.0001 | 0.6531 | 0.0424 | 0.0001 |
| VAS Post-nasal Drip | 6.02 (2.11) | 3.15 (2.14) | 1.55 (1.86) | <0.0001 | 0.999 | 0.0043 | <0.0001 |
| VAS Olfaction | 1.33 (2.22) | 0.62 (1.11) | 0.22 (0.49) | <0.0001 | 0.0163 | <0.0001 | 0.0008 |
| VAS Snoring | 1.32 (2.35) | 0.87 (1.67) | 0.37 (0.84) | <0.0001 | 0.0203 | <0.0001 | 0.0005 |
| VAS Bronchial Discomfort | 1.01 (2.41) | 1.05 (2.52) | 0.9 (2.19) | 0.1266 | |||
| VAS Ocular Discomfort | 2.28 (2.64) | 0.98 (1.53) | 0.34 (0.81) | <0.0001 | 1.0000 | 0.2238 | <0.0001 |
| VAS Quality of Life | 6.9 (2.11) | 3.79 (1.76) | 1.78 (1.97) | <0.0001 | 0.0014 | 0.9999 | <0.0001 |
| VAS Quality of Sleep | 7.05 (2.06) | 3.69 (1.75) | 1.67 (1.92) | <0.0001 | 0.0010 | 0.9999 | <0.0001 |
| VAS Impact on Daily Activities | 6.57 (2.24) | 3.33 (1.87) | 1.63 (2.12) | <0.0001 | 0.0050 | 0.9999 | <0.0001 |